NYSE:LLY - Eli Lilly and Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $231.29
Forecasted Upside: -4.79 %
Number of Analysts: 14
Breakdown:
0 Sell Ratings
2 Hold Ratings
11 Buy Ratings
1 Strong Buy Ratings

^$242.92 As of 07/28/2021 10:33 AM ET

▼ -0.66 (-0.27%)

1 month | 3 months | 12 months

Get New Eli Lilly and Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for LLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LLY

^$231.29

▼ -4.79% Downside Potential

This price target is based on 14 analysts offering 12 month price targets for Eli Lilly and in the last 3 months. The average price target is $231.29, with a high forecast of $300.00 and a low forecast of $144.00. The average price target represents a -4.79% upside from the last price of $242.92.

Current Consensus is Buy

The current consensus among 14 contributing investment analysts is to buy stock in Eli Lilly and. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

1 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/4/2020

1 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/4/2020

1 strong buy ratings
9 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/2/2020

1 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/31/2020

1 strong buy ratings
10 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/29/2021

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/29/2021

1 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/28/2021

1 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/28/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
7/7/2021	Mizuho	Reiterated Rating	Buy	$250.00	Low
7/6/2021	Barclays	Boost Price Target	Overweight	$227.00 ➝ $250.00	Low
7/2/2021	Truist Securities	Boost Price Target	Buy	$225.00 ➝ $262.00	Low
7/2/2021	Truist	Boost Price Target	Buy ➝ Buy	$225.00 ➝ $262.00	Low
6/24/2021	Cantor Fitzgerald	Boost Price Target	Positive ➝ Overweight	$245.00 ➝ $300.00	High
6/24/2021	Cowen	Boost Price Target	Positive ➝ Outperform	$235.00 ➝ $250.00	High
6/15/2021	JPMorgan Chase & Co.	Boost Price Target	Overweight	$240.00 ➝ $260.00	Low
6/14/2021	The Goldman Sachs Group	Boost Price Target	Positive ➝ Conviction-Buy	$252.00 ➝ $270.00	Low
6/8/2021	Truist Securities	Reiterated Rating	Buy	$225.00	Medium
6/8/2021	Truist Financial	Reiterated Rating	Buy	$225.00	Medium
4/28/2021	Morgan Stanley	Lower Price Target	Overweight	$217.00 ➝ $207.00	Medium
4/28/2021	Mizuho	Lower Price Target	Buy	$228.00 ➝ $216.00	Medium
4/28/2021	Barclays	Lower Price Target	Overweight	$232.00 ➝ $227.00	Medium
3/15/2021	Truist Securities	Boost Price Target	Buy	$215.00 ➝ $225.00	High
2/12/2021	Cowen	Boost Price Target	Outperform	$195.00 ➝ $235.00	Low
2/4/2021	Morgan Stanley	Boost Price Target	Overweight	$190.00 ➝ $217.00	Medium
2/1/2021	Truist	Boost Price Target		$200.00 ➝ $215.00	Low
2/1/2021	Mizuho	Boost Price Target	Buy	$222.00 ➝ $228.00	Low
2/1/2021	Barclays	Boost Price Target	Overweight	$190.00 ➝ $232.00	Low
1/22/2021	Bank of America	Boost Price Target	Buy	$195.00 ➝ $225.00	Medium
1/19/2021	Mizuho	Upgrade	Neutral ➝ Buy	$164.00 ➝ $222.00	N/A
1/12/2021	Truist	Boost Price Target		$182.00 ➝ $200.00	Medium
12/16/2020	Mizuho	Boost Price Target	Neutral	$156.00 ➝ $164.00	High
12/10/2020	Wolfe Research	Upgrade	Peer Perform ➝ Outperform	$147.00 ➝ $183.00	Medium
11/17/2020	Mizuho	Lower Price Target	Neutral	$164.00 ➝ $156.00	Low
11/10/2020	Sanford C. Bernstein	Initiated Coverage	Market Perform	$150.00	Low
10/28/2020	Morgan Stanley	Lower Price Target	Overweight	$176.00 ➝ $170.00	Low
10/23/2020	Truist	Initiated Coverage	Buy	$180.00	Medium
10/16/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$190.00 ➝ $200.00	Low
9/29/2020	Berenberg Bank	Initiated Coverage	Hold	$144.00	Medium
9/3/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$149.55 ➝ $176.00	High
8/14/2020	Morgan Stanley	Boost Price Target	Equal Weight	$148.00 ➝ $157.00	Low
6/29/2020	Mizuho	Boost Price Target	Neutral	$155.00 ➝ $164.00	Low
6/19/2020	Bank of America	Reiterated Rating	Buy	$180.00	Low
6/17/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$175.00 ➝ $190.00	Low
6/16/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$182.00	High
4/24/2020	Mizuho	Boost Price Target	Buy	$148.00 ➝ $155.00	Low
4/24/2020	Cfra	Boost Price Target	Hold	$146.00 ➝ $167.00	Low
4/24/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$156.00 ➝ $185.00	Low
4/20/2020	UBS Group	Downgrade	Buy ➝ Neutral	$157.00 ➝ $158.00	High
4/19/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight		Low
4/15/2020	Cowen	Boost Price Target	Outperform	$145.00 ➝ $160.00	Medium
4/9/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$148.00	Low
4/2/2020	Mizuho	Reiterated Rating	Hold	$148.00	Medium
4/2/2020	Morgan Stanley	Lower Price Target	Overweight ➝ Equal Weight	$150.00 ➝ $148.00	High
3/11/2020	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy	$168.00	Medium
2/27/2020	Barclays	Initiated Coverage	Overweight		High
2/18/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$156.00	Low
2/5/2020	Mizuho	Initiated Coverage	Neutral	$148.00	Low
2/3/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$156.00	Medium
12/30/2019	Argus	Boost Price Target	Buy	$145.00 ➝ $165.00	Low
12/18/2019	JPMorgan Chase & Co.	Boost Price Target	Overweight	$140.00 ➝ $150.00	High
12/18/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$116.00 ➝ $150.00	High
12/2/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$143.00	Low
10/17/2019	UBS Group	Lower Price Target	Buy	$134.00 ➝ $133.00	Low
10/16/2019	Bank of America	Initiated Coverage	Buy	$133.00	Low
9/10/2019	Bank of America	Set Price Target	Neutral	$118.00 ➝ $120.00	High
5/28/2019	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$135.00	Low
5/1/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $133.00	Low
4/30/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$143.00	Medium
4/23/2019	Edward Jones	Upgrade	Hold ➝ Buy	$117.49	Low
4/22/2019	BMO Capital Markets	Lower Price Target	Outperform	$130.00	Medium
4/14/2019	Barclays	Reiterated Rating	Buy	$140.00	Low
4/11/2019	Guggenheim	Downgrade	Buy ➝ Neutral	$125.84	Low
3/22/2019	Credit Suisse Group	Set Price Target	Hold	$121.00	Low
3/21/2019	Bank of America	Set Price Target	Hold	$129.00	Low
3/20/2019	UBS Group	Initiated Coverage	Buy	$140.00 ➝ $74.51	Low
3/12/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$140.00	Low
2/26/2019	Citigroup	Set Price Target	Hold	$124.00	Medium
2/8/2019	UBS Group	Lower Price Target	Average	$107.53 ➝ $100.00	Low
2/4/2019	Cantor Fitzgerald	Reiterated Rating	Buy		Low
1/23/2019	UBS Group	Initiated Coverage	Buy ➝ Buy	$131.00	Low
1/20/2019	Barclays	Reiterated Rating	Buy	$130.00	Low
12/27/2018	Argus	Reiterated Rating	Buy		Medium
12/24/2018	BMO Capital Markets	Boost Price Target	Outperform	$124.00 ➝ $132.00	Low
12/20/2018	Morgan Stanley	Set Price Target	Hold	$116.00	High
12/19/2018	BMO Capital Markets	Reiterated Rating	Buy		Low
12/2/2018	Citigroup	Downgrade	Buy ➝ Neutral	$113.00	Low
11/26/2018	Citigroup	Downgrade	Buy ➝ Neutral	$115.00	Low
11/7/2018	Societe Generale	Set Price Target	Hold	$106.00	High
10/31/2018	Credit Suisse Group	Upgrade	Underperform ➝ Neutral		Medium
10/23/2018	Wolfe Research	Initiated Coverage	Market Perform	$119.00	Low
10/17/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$128.00	Medium
10/12/2018	Barclays	Boost Price Target	Overweight	$112.00 ➝ $120.00	Low
10/8/2018	Guggenheim	Initiated Coverage	Buy ➝ Buy		Low
10/5/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$123.00	Low
10/4/2018	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$107.00 ➝ $130.00	High
10/3/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$90.00 ➝ $107.00	Medium
10/1/2018	SunTrust Banks	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $123.00	Low
9/27/2018	Cantor Fitzgerald	Set Price Target	Buy	$110.00	Low
9/26/2018	JPMorgan Chase & Co.	Set Price Target	Not Rated ➝ Overweight	$117.00	Low
9/18/2018	Barclays	Reiterated Rating	Overweight	$107.00 ➝ $112.00	Low
9/17/2018	Cantor Fitzgerald	Set Price Target	Buy	$110.00	Low
9/7/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$98.00 ➝ $107.00	Medium
7/31/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$93.00 ➝ $102.00	Low
7/31/2018	SunTrust Banks	Reiterated Rating	Buy	$105.00	Low
7/25/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$90.00 ➝ $94.00	Medium
7/25/2018	Credit Suisse Group	Boost Price Target	Underperform ➝ Underperform	$84.00 ➝ $86.00	High
7/25/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$80.00 ➝ $90.00	High
7/25/2018	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$100.00 ➝ $110.00	High
7/25/2018	Berenberg Bank	Downgrade	Buy ➝ Hold	$99.00	High
7/25/2018	The Goldman Sachs Group	Set Price Target	Neutral	$100.00	High
7/24/2018	Cowen	Set Price Target	Buy	$105.00	High
7/24/2018	Cantor Fitzgerald	Set Price Target	Buy	$100.00	High
7/19/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ $89.43	$78.00 ➝ $80.00	Medium
7/17/2018	Cantor Fitzgerald	Set Price Target	Buy	$100.00	Low
7/17/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$86.00 ➝ $90.00	Low
7/15/2018	Jefferies Financial Group	Set Price Target	Buy	$100.00	Low
7/13/2018	Credit Suisse Group	Set Price Target	Hold	$84.00	Low
7/9/2018	Cantor Fitzgerald	Set Price Target	Buy	$100.00	Low
6/22/2018	DZ Bank	Reiterated Rating	Buy ➝ Hold		Low
6/21/2018	Credit Suisse Group	Boost Price Target	Underperform ➝ Underperform	$82.00 ➝ $84.00	Low
6/11/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$100.00	Low
6/7/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$100.00	Low
5/22/2018	Barclays	Set Price Target	Buy	$98.00	Low
5/15/2018	Credit Suisse Group	Set Price Target	Hold	$82.00	Low
5/10/2018	BMO Capital Markets	Reiterated Rating	Hold	$78.00	Low
4/25/2018	BMO Capital Markets	Lower Price Target	Market Perform ➝ Market Perform	$79.00 ➝ $78.00	Medium
4/24/2018	BMO Capital Markets	Reiterated Rating	Hold	$79.00	Medium
4/22/2018	Credit Suisse Group	Set Price Target	Hold	$80.00	Medium
4/18/2018	HC Wainwright	Reiterated Rating	Buy		Low
4/13/2018	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$74.00 ➝ $79.00	Low
4/13/2018	Jefferies Financial Group	Set Price Target	Buy	$90.00	Low
4/4/2018	BMO Capital Markets	Reiterated Rating	Sell	$74.00	Medium
3/23/2018	Jefferies Financial Group	Reiterated Rating	Buy	$91.00	Medium
2/26/2018	Jefferies Financial Group	Set Price Target	Buy	$93.00	Low
2/26/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$105.00	Medium
2/2/2018	Credit Suisse Group	Reiterated Rating	Hold	$80.00	Low
2/1/2018	Bank of America	Lower Price Target	Neutral ➝ Neutral	$88.00 ➝ $86.00	Low
2/1/2018	BMO Capital Markets	Boost Price Target	Underperform ➝ Underperform	$73.00 ➝ $74.00	Low
1/22/2018	Credit Suisse Group	Downgrade	Neutral ➝ Underperform	$82.00	Low
1/16/2018	Jefferies Financial Group	Set Price Target	Buy	$100.00	High
1/16/2018	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$86.98 ➝ $95.00	High
1/5/2018	Argus	Upgrade	Hold ➝ Buy	$85.52 ➝ $115.00	Medium
12/13/2017	Credit Suisse Group	Reiterated Rating	Hold		Medium
12/12/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	Low
12/5/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	Low
11/21/2017	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$86.00 ➝ $90.00	N/A
11/1/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	N/A
10/26/2017	Berenberg Bank	Reiterated Rating	Buy	$98.00	N/A
10/24/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	N/A
10/23/2017	SVB Leerink	Boost Price Target	Market Perform	$92.00 ➝ $93.00	N/A
10/16/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	N/A
10/13/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$105.00	N/A
10/13/2017	Barclays	Boost Price Target	Overweight	$90.00 ➝ $98.00	N/A
10/10/2017	BMO Capital Markets	Boost Price Target	Underperform	$71.00 ➝ $73.00	N/A
10/10/2017	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$84.23 ➝ $88.00	N/A
10/6/2017	Morgan Stanley	Set Price Target	Hold	$86.00	N/A
10/5/2017	The Goldman Sachs Group	Reiterated Rating	Buy	$92.00 ➝ $95.00	N/A
10/4/2017	Cowen	Reiterated Rating	Buy	$95.00	Low
9/28/2017	BMO Capital Markets	Reiterated Rating	Sell	$71.00	Low
9/15/2017	Morgan Stanley	Reiterated Rating	Hold	$86.00	Low
9/11/2017	Jefferies Financial Group	Reiterated Rating	Buy	$89.00 ➝ $89.00	Low
9/8/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$103.00 ➝ $105.00	Low
9/6/2017	BMO Capital Markets	Reiterated Rating	Underperform	$73.00 ➝ $71.00	Low
8/31/2017	Jefferies Financial Group	Reiterated Rating	Buy	$89.00	Medium
8/31/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$103.00	Low
8/31/2017	SVB Leerink	Reiterated Rating	Hold		Low
8/24/2017	Jefferies Financial Group	Reiterated Rating	Buy	$94.00 ➝ $89.00	Low
8/16/2017	BMO Capital Markets	Reiterated Rating	Sell	$73.00	High
8/4/2017	Berenberg Bank	Reiterated Rating	Buy	$98.00	Low
8/4/2017	BMO Capital Markets	Reiterated Rating	Sell	$73.00	Low
7/27/2017	Berenberg Bank	Reiterated Rating	Buy	$100.00	Low
7/26/2017	UBS Group	Downgrade	Hold	$85.00	Medium
7/26/2017	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$90.00 ➝ $90.00	Low
7/26/2017	BMO Capital Markets	Reiterated Rating	Underperform	$73.00	Low
7/26/2017	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$93.00 ➝ $90.00	Low
7/17/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$90.00 ➝ $91.00	Low
7/13/2017	Jefferies Financial Group	Reiterated Rating	Buy	$93.00 ➝ $96.00	Low
7/4/2017	Citigroup	Reiterated Rating	Buy	$100.00	Low
7/4/2017	Barclays	Boost Price Target	Overweight	$85.00 ➝ $90.00	Low
6/22/2017	Jefferies Financial Group	Reiterated Rating	Buy	$93.00	Low
6/5/2017	Jefferies Financial Group	Reiterated Rating	Buy	$92.00	Low
5/30/2017	Jefferies Financial Group	Reiterated Rating	Buy		Low
5/21/2017	Sanford C. Bernstein	Reiterated Rating	Outperform	$88.00	Medium
5/16/2017	The Goldman Sachs Group	Reiterated Rating	Conviction-Buy ➝ Buy	$92.00	High
4/29/2017	BMO Capital Markets	Reiterated Rating	Underperform	$71.00 ➝ $73.00	Low
4/29/2017	Jefferies Financial Group	Reiterated Rating	Buy	$94.00 ➝ $92.00	Low
4/27/2017	Argus	Downgrade	Buy ➝ Hold	$64.18 ➝ $81.00	Low
4/25/2017	BMO Capital Markets	Set Price Target	Sell	$71.00	Low
4/19/2017	Citigroup	Boost Price Target	Buy	$92.00 ➝ $100.00	Low
4/19/2017	Credit Suisse Group	Reiterated Rating	Outperform	$87.00	Low
4/17/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$100.00	Medium
4/17/2017	Cowen	Boost Price Target	Outperform	$85.00 ➝ $95.00	Medium
4/17/2017	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$82.00	High
4/17/2017	BMO Capital Markets	Downgrade	Market Perform ➝ Underperform	$73.00 ➝ $71.00	High
4/10/2017	Jefferies Financial Group	Reiterated Rating	Buy	$97.00	Low
4/7/2017	Barclays	Boost Price Target	Overweight	$85.00 ➝ $90.00	Low
4/6/2017	Citigroup	Reiterated Rating	Buy	$100.00	Low
3/21/2017	Credit Suisse Group	Reiterated Rating	Buy		Low
3/20/2017	SVB Leerink	Reiterated Rating	Outperform		Low
3/20/2017	UBS Group	Boost Price Target	Neutral ➝ Neutral	$70.00 ➝ $85.00	N/A
3/11/2017	Jefferies Financial Group	Reiterated Rating	Buy	$95.00 ➝ $97.00	N/A
2/17/2017	Jefferies Financial Group	Reiterated Rating	Buy		N/A
2/1/2017	Barclays	Boost Price Target	Buy	$80.00 ➝ $85.00	N/A
2/1/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$70.00 ➝ $73.00	N/A
1/20/2017	Jefferies Financial Group	Boost Price Target	Buy	$90.00 ➝ $93.00	N/A
1/19/2017	Citigroup	Set Price Target	Buy	$100.00	N/A
1/18/2017	The Goldman Sachs Group	Reiterated Rating	Conviction-Buy	$92.00	N/A
1/18/2017	Credit Suisse Group	Reiterated Rating	Outperform	$87.00	N/A
12/21/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$82.00 ➝ $85.00	N/A
12/19/2016	Credit Suisse Group	Reiterated Rating	Focus List	$87.00	N/A
12/16/2016	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$73.00 ➝ $82.00	N/A
12/15/2016	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy		N/A
12/14/2016	BMO Capital Markets	Reiterated Rating	Hold	$64.00	N/A
12/7/2016	Sanford C. Bernstein	Reiterated Rating	Overweight		N/A
11/26/2016	SVB Leerink	Reiterated Rating	Outperform	$102.00 ➝ $92.00	N/A
11/26/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A
11/25/2016	Atlantic Securities	Downgrade	Overweight ➝ Neutral		N/A
11/24/2016	JPMorgan Chase & Co.	Set Price Target	Buy	$85.00	N/A
11/24/2016	Morgan Stanley	Set Price Target	Hold	$73.00	N/A
11/23/2016	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$91.00 ➝ $64.00	N/A
11/8/2016	Citigroup	Reiterated Rating	Buy		N/A
10/28/2016	Jefferies Financial Group	Reiterated Rating	Buy	$105.00 ➝ $100.00	N/A
10/27/2016	Societe Generale	Reiterated Rating	Hold	$78.00	N/A
10/26/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$95.00	N/A
10/9/2016	SVB Leerink	Reiterated Rating	Buy	$103.00	N/A
10/3/2016	BMO Capital Markets	Reiterated Rating	Buy	$94.00	N/A
9/27/2016	BMO Capital Markets	Reiterated Rating	Outperform	$94.00	N/A
9/27/2016	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$89.00 ➝ $95.00	N/A
9/20/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		N/A
9/14/2016	Jefferies Financial Group	Reiterated Rating	Buy	$105.00	N/A
9/8/2016	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$92.00 ➝ $95.00	N/A
8/13/2016	SVB Leerink	Reiterated Rating	Outperform	$105.00	N/A
8/3/2016	Citigroup	Reiterated Rating	Buy		N/A
8/2/2016	Argus	Boost Price Target	Buy	$90.00 ➝ $95.00	N/A

(Data available from 7/28/2016 forward)

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo.The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Today's Range

Now: $242.92

$242.62

$244.74

50 Day Range

MA: $222.78

$196.51

$244.15

52 Week Range

Now: $242.92

$129.21

$245.28

Volume

402 shs

Average Volume

3,785,587 shs

Market Capitalization

$232.97 billion

P/E Ratio

36.31

Dividend Yield

1.40%

Beta

0.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Eli Lilly and?

The following sell-side analysts have issued reports on Eli Lilly and in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, Cantor Fitzgerald, Cowen Inc, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Sanford C. Bernstein, The Goldman Sachs Group, Inc., Truist, Truist Financial Co., Truist Securities, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for LLY.

What is the current price target for Eli Lilly and?

14 Wall Street analysts have set twelve-month price targets for Eli Lilly and in the last year. Their average twelve-month price target is $231.29, suggesting a possible downside of 5.0%. Cantor Fitzgerald has the highest price target set, predicting LLY will reach $300.00 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of $144.00 for Eli Lilly and in the next year.
View the latest price targets for LLY.

What is the current consensus analyst rating for Eli Lilly and?

Eli Lilly and currently has 2 hold ratings, 11 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LLY will outperform the market and that investors should add to their positions of Eli Lilly and.
View the latest ratings for LLY.

What other companies compete with Eli Lilly and?

Other companies that are similar to Eli Lilly and include Johnson & Johnson, Pfizer, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb, Zoetis, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Nektar Therapeutics, Pacira BioSciences, Corcept Therapeutics, Supernus Pharmaceuticals and Endo International.

How do I contact Eli Lilly and's investor relations team?

Eli Lilly and's physical mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company's listed phone number is (317) 276-2000 and its investor relations email address is [email protected] The official website for Eli Lilly and is www.lilly.com.